Current and future directions in theranostics for neuroendocrine prostate cancer

Authors: Belge Bilgin, Gokce ^{a, ⁎}, Lucien-Matteoni, Fabrice ^b, Chaudhuri, Aadel A. ^c, Orme, Jacob J. ^d, Childs, Daniel S. ^d, Muniz, Miguel ^d, Li, Gary G. ^e, Chauhan, Pradeep S. ^c, Lee, SeungBaek ^a, Gupta, Sounak ^f, Thorpe, Matthew P. ^a, Johnson, Derek R. ^a, Johnson, Geoffrey B. ^{a, g}, Kendi, Ayse Tuba ^a, Sartor, Oliver ^{a, b, d}

Source: In Cancer Treatment Reviews May 2025 136

Survival Patterns Based on First-site–specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?

Authors: Ahmed, Mohamed E., Mahmoud, Ahmed M., Reitano, Guiseppe, Zeina, Wael, Lehner, Kelly, Day, Carter A., Riaz, Irbaz, Childs, Daniel S., Orme, Jacob J., Tuba Kendi, A., Johnson, Geoffrey B., Jeffrey Karnes, R., Kwon, Eugene D., Andrews, Jack R.

Source: In European Urology Open Science August 2024 66:38-45

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Authors: Orme, Jacob J., Taza, Fadi, De Sarkar, Navonil, Tewari, Alok K., Arsalan Naqvi, Syed, Riaz, Irbaz B., Childs, Daniel S., Omar, Noha, Adra, Nabil, Ashkar, Ryan, Cheng, Heather H., Schweizer, Michael T., Sokolova, Alexandra O., Agarwal, Neeraj, Barata, Pedro, Sartor, Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., McClure, Heather, Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Mehra, Niven, Nelson, Peter S., Hwang, Justin, Dehm, Scott M., Shi, Qian, Fleischmann, Zoe, Sokol, Ethan S., Elliott, Andrew, Huang, Haojie, Bryce, Alan, Marshall, Catherine H., Antonarakis, Emmanuel S.

Source: In European Urology Oncology August 2024 7(4):877-887

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Authors: Muniz, Miguel, Loprinzi, Charles L, Orme, Jacob J, Koch, Regina M, Mahmoud, Ahmed M, Kase, Adam M, Riaz, Irbaz B, Andrews, Jack R, Thorpe, Matthew P, Johnson, Geoffrey B, Kendi, Ayse T, Kwon, Eugene D, Nauseef, Jones T, Morgans, Alicia K, Sartor, Oliver, Childs, Daniel S

Source: In Cancer Treatment Reviews June 2024 127

In‐field prostate cancer recurrence following radical prostatectomy and salvage radiation.

Authors: Martin, Austin, Mahmoud, Ahmed M., Britton, Cameron J., Fadel, Anthony, Ahmed, Mohamed E., Sharma, Vidit, Childs, Daniel S., Johnson, Geoffrey B., Davis, Brian J., Mynderse, Lance, Lomas, Derek, Woodrum, David, Frendl, Daniel, Karnes, Jeffrey R., Tollefson, Matthew K., Kwon, Eugene D., Andrews, Jack R.

Source: BJU International; Apr2025, Vol. 135 Issue 4, p668-674, 7p

Subject Terms: PROSTATE cancer, RADICAL prostatectomy, CRYOSURGERY, DISEASE relapse, ANDROGEN deprivation therapy, PROGRESSION-free survival, INTRAOPERATIVE radiotherapy, THERAPEUTICS

Large language models (LLMs) for inferring genomic characteristics and facilitating genomic literacy in prostate cancer (PCa) patients.

Authors: Naqvi, Syed Arsalan Ahmed, Ayub, Umair, Khan, Muhammad Ali, Khoury, Peter R., Ravichandar, Deepak B, Witte, Owen H., Childs, Daniel S, Orme, Jacob, Zakharia, Yousef, Singh, Parminder, Bryce, Alan Haruo, Riaz, Irbaz Bin

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p261-261, 288p

Choice of androgen receptor pathway inhibitors (ARPi) by disease volume and timing of metastases in metastatic hormone sensitive prostate cancer (mHSPC).

Authors: Naqvi, Syed Arsalan Ahmed, Faisal, Kunwer Sufyan, Khakwani, Kaneez Zahra Rubab, Childs, Daniel S, Orme, Jacob, Andrews, Jack, Ravi, Praful, Hussain, Syed A., Agarwal, Neeraj, Singh, Parminder, Zakharia, Yousef, Sartor, Alton Oliver, Riaz, Irbaz Bin, Bryce, Alan Haruo

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p184-184, 288p

Inferring ECOG performance status (PS) using large language models in patients with advanced prostate cancer.

Authors: Raina, Ammad, Muniz, Miguel, Anjum, Muhammad Umair, Ayub, Umair, Naqvi, Syed Arsalan Ahmed, Jajja, Salman Ayub, Yum, Ji-Eun, Zhou, Ben, Yu, Nathan Y, Abdul-Muhsin, Haidar, Sartor, Alton Oliver, Orme, Jacob, Singh, Parminder, Zakharia, Yousef, Childs, Daniel S, Riaz, Irbaz Bin

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p136-136, 288p

Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.

Authors: Jajja, Salman Ayub, Naqvi, Syed Arsalan Ahmed, Khan, Muhammad Ali, Afzal, Muhammad Umar, Anjum, Muhammad Umair, Raina, Ammad, Jain, Prateek, Swati, Fnu, Riaz, Zaryab Bin, Childs, Daniel S, Cobran, Ewan Kemar, Bryce, Alan Haruo, Zakharia, Yousef, Singh, Parminder, Riaz, Irbaz Bin

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p134-134, 288p

Sociodemographic predictors of the late-stage diagnosis in patients with prostate cancer: A retrospective cohort study.

Authors: Khan, Muhammad Ali, Afzal, Muhammad Umar, Raina, Ammad, Riaz, Zaryab Bin, Warraich, Kainat, Sartor, Alton Oliver, Bryce, Alan Haruo, Singh, Parminder, Childs, Daniel S, Orme, Jacob, Abdul-Muhsin, Haidar, Kase, Adam McLain, Moore, Cassandra N., Agarwal, Neeraj, Zakharia, Yousef, Cobran, Ewan Kemar, Riaz, Irbaz Bin

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p132-132, 288p

Safety evaluation of stereotactic body radiation therapy (SBRT) during lutetium-177-PSMA-617 (177Lu-PSMA-617) treatment for patients with metastatic prostate cancer.

Authors: Kessel, Adam, Muniz, Miguel, O'Byrne, Jamie T, Phillips, Ryan, Park, Sean Sunghun, Davis, Brian, Stish, Brad J., Choo, Chunhee Richard, Merrell, Kenneth, Kwon, Eugene D., Johnson, Geoffrey, Quevedo, Fernando, Orme, Jacob, Childs, Daniel S, Wilson, Jessica M

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p129-129, 288p

Clinical efficacy of enfortumab vedotin-pembrolizumab (EV-P) in locally advanced (LA) or metastatic urothelial carcinoma (mUC): A real-world retrospective study.

Authors: Jain, Prateek, Naqvi, Syed Arsalan Ahmed, Anjum, Muhammad Umair, Khan, Muhammad Ali, Afzal, Muhammad Umar, Yum, Ji-Eun, Warraich, Kainat, Jajja, Salman Ayub, Swati, Fnu, Tripathi, Nikita, Childs, Daniel S, Orme, Jacob, Zakharia, Yousef, Tyson, Mark, Yu, Nathan Y, Riaz, Irbaz Bin, Singh, Parminder

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, p745-745, 242p

Olanzapine for managing side effects from tyrosine-kinase inhibitors.

Authors: Koch, Regina, Muniz, Miguel, Peskey, Candy, Jatoi, Aminah, Ruddy, Kathryn Jean, Orme, Jacob, Pagliaro, Lance C., Quevedo, Fernando, Costello, Brian Addis, Megan, Spychalla, Heath, Elisabeth I., Zakharia, Yousef, Singh, Parminder, Riaz, Irbaz Bin, Cathcart-Rake, Elizabeth Jane, D'Andre, Stacy D., Loprinzi, Charles L., Childs, Daniel S

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, p524-524, 177p

Automated risk stratification in localized prostate cancer using an AI-assisted framework.

Authors: Ayub, Umair, Naqvi, Syed Arsalan Ahmed, Jajja, Salman Ayub, Afzal, Muhammad Umar, Khakwani, Kaneez Zahra Rubab, Andrews, Jack, Bryce, Alan Haruo, Sartor, Alton Oliver, Abdul-Muhsin, Haidar, Childs, Daniel S, Orme, Jacob, Baral, Chitta, Agarwal, Neeraj, Pal, Sumanta Kumar, Tripathi, Abhishek, Singh, Parminder, Zakharia, Yousef, Riaz, Irbaz Bin

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, p341-341, 125p

Utility of post-treatment SPECT/CT for identifying disease progression in patients with mCRPC treated with 177 Lu-PSMA-617.

Authors: Muniz, Miguel, Sartor, Alton Oliver, Orme, Jacob, Koch, Regina, Quevedo, Fernando, Kase, Adam McLain, Riaz, Irbaz Bin, Thorpe, Matthew, Kendi, Ayse T., Bilgin, Gokce Belge, Nikanpour, Yalda, Johnson, Geoffrey, Kwon, Eugene D., Childs, Daniel S

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, p114-114, 288p

Outcomes for 177 Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.

Authors: Muniz, Miguel, Sartor, Alton Oliver, Orme, Jacob, Koch, Regina, Quevedo, Fernando, Kase, Adam McLain, Riaz, Irbaz Bin, Naqvi, Syed Arsalan Ahmed, Andrews, Jack, Thorpe, Matthew, Kendi, Ayse T., Bilgin, Gokce Belge, Johnson, Geoffrey, Kwon, Eugene D., Childs, Daniel S

Source: Journal of Clinical Oncology; 2/10/2025 Supplement5, Vol. 43, p112-112, 288p

Perceptions of Hematology Among Palliative Care Physicians: Results of a Nationwide Survey

Authors: Santivasi, Wil L., Childs, Daniel S., Wu, Kelly L., Partain, Daniel K., Litzow, Mark R., LeBlanc, Thomas W., Strand, Jacob J.

Source: In Journal of Pain and Symptom Management November 2021 62(5):949-959

Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)

Authors: Hertz, Daniel L., Childs, Daniel S., Park, Susanna B., Faithfull, Sara, Ke, Yu, Ali, Nadeen T., McGlown, Sheila Marie, Chan, Alexandre, Grech, Lisa B., Loprinzi, Charles L., Ruddy, Kathryn J., Lustberg, Maryam

Source: In Cancer Treatment Reviews September 2021 99

A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis

Authors: Mosalem, Osama, Tan, Winston, Bryce, Alan H., Dronca, Roxana S., Childs, Daniel S., Pagliaro, Lance C., Orme, Jacob J., Kase, Adam M.

Source: Prostate Cancer and Prostatic Diseases; March 2025, Vol. 28 Issue: 1 p138-144, 7p

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [¹⁷⁷Lu]Lu-PSMA-617.

Authors: Muniz, Miguel, Sartor, Oliver, Orme, Jacob J., Koch, Regina M., Rosenow, Hana R., Mahmoud, Ahmed M., Andrews, Jack R., Kase, Adam M., Riaz, Irbaz B., Belge Bilgin, Gokce, Thorpe, Matthew P., Kendi, A. Tuba, Johnson, Geoffrey B., Ravi, Praful, Kwon, Eugene D., Childs, Daniel S.

Source: Journal of Nuclear Medicine; Dc2024, Vol. 65 Issue 12, p1932-1938, 7p